Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trialPablo Ryan, Estebán Martínez, José L Blanco et al.|The Lancet HIV|2025Cited by 22
Trends in Hepatitis C Virus Infection Prevalence Among People With HIV in Spain Over 2 Decades (2002–2023)Juan Berenguer, Juan González‐García, Julia Barrado et al.|Clinical Infectious Diseases|2025Cited by 5
Epidemiological, clinical and mortality trends in people living with HIV over 60 years in the PISCIS population-based cohort from Catalonia and Balearic IslandsAndreu Bruguera, Juliana Reyes‐Urueña, Daniel K. Nomah et al.|AIDS|2024Cited by 1